EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro

Xinyi Guo, James C Fredenburgh, Jeffrey I Weitz

Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3981-3988

DOI: 10.1016/j.jtha.2026.08.002 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Xinyi Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medical…. Hauptthemen laut MEDLINE: Thrombin, Blood Coagulation, Antibodies, Monoclonal, Humanized, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Medical devices, such as central venous catheters and mechanical heart valves (MHVs), are associated with an increased risk of thrombosis. Clotting on these devices is initiated by contact with the system surface. Adsorbed factor (F)XII undergoes autoactivation and activates FXI, which then propagates coagulation. Abelacimab, asundexian, and milvexian are FXI or FXIa inhibitors currently undergoing or having completed phase 3 evaluation. OBJECTIVES: To compare the effects of abelacimab, asundexian, and milvexian on activated partial thromboplastin time (APTT), catheter-induced clotting, and device-induced thrombin generation. METHODS: The effects of abelacimab, asundexian, and milvexian on APTT (measured with HemosIL APTT-SP reagent), catheter-induced clotting, and thrombin generation induced by catheter segments or MHV leaflets were assessed in human platelet-poor plasma. Thrombin generation was monitored over time using a fluorogenic substrate, and peak thrombin and endogenous thrombin potential were quantified. RESULTS: Abelacimab, asundexian, and milvexian prolonged APTT and catheter-induced clotting time and attenuated device-induced thrombin generation in a concentration-dependent manner. At clinically relevant concentrations, abelacimab and milvexian had more pronounced effects on APTT, catheter-induced clotting, and device-induced thrombin generation than asundexian. Even at the highest concentration tested, asundexian showed less inhibition of device-induced thrombin generation than the other inhibitors. CONCLUSION: At the concentrations achieved by the dosing regimens evaluated in the phase 3 trials, abelacimab and milvexian had greater effects on APTT, catheter-induced clotting, and thrombin generation induced by catheters or MHVs than asundexian.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinBlood CoagulationAntibodies, Monoclonal, HumanizedAnticoagulantsHeart Valve ProsthesisCatheterization, Central VenousHumansPartial Thromboplastin TimeBenzamidesHydrocarbons, FluorinatedPyrimidinesTriazoles

Stichwörter der Autor:innen

anticoagulantscathetersfactor XIheart valvesthrombosis

Substanzen

ThrombinAntibodies, Monoclonal, HumanizedAnticoagulantsasundexianmilvexianBenzamidesHydrocarbons, FluorinatedPyrimidinesTriazoles

Autor:innen und Institutionen

  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada; Department…

Förderung

  • Heart and Stroke Foundation of Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Guo, X., Fredenburgh, J. C., & Weitz, J. I. (2026). Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro. Journal of Thrombosis and Haemostasis, 24(11), 3981-3988. https://doi.org/10.1016/j.jtha.2026.08.002

Vancouver

Guo X, Fredenburgh JC, Weitz JI. Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro. Journal of Thrombosis and Haemostasis. 2026;24(11):3981-3988. doi:10.1016/j.jtha.2026.08.002

BibTeX
@article{Guo2026,
  author = {Guo, Xinyi and Fredenburgh, James C and Weitz, Jeffrey I},
  title = {Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {3981--3988},
  doi = {10.1016/j.jtha.2026.08.002}
}
Kostenlos starten →